MTPConnect and CII sign MoU to boost growth


Friday, 01 September, 2017

MTPConnect and CII sign MoU to boost growth

MTPConnect — the Medical Technologies, Biotechnologies and Pharmaceuticals Industry Growth Centre — and the Confederation of Indian Industry (CII) — a not-for-profit, industry-led and industry-managed organisation — have signed a memorandum of understanding (MoU) to work collaboratively to boost the innovative medical technology, biotechnology and pharmaceutical sectors in India and Australia.

The MoU was signed during Australia-India Business week in New Delhi, by MTPConnect Chair and CEO of Standards Australia Dr Bronwyn Evans and CII Deputy Director General Amita Sarkar.

The MoU will bring the two organisations together to support activities such as inbound and outbound missions, exchanging key information on issues and trends, introductions and in-market support in both countries, and joint events and projects. Dr Evans said, “The partnership will build on the recent MoU between the Indian and Australian governments on cooperation in the field of health and medicine, and the Australia-India Strategic Research Fund, by providing a platform for knowledge sharing and collaboration to support the growth of the medical technology, biotechnology and pharmaceutical sectors in our world-leading countries.”

In 2017, Prime Ministers Malcolm Turnbull and Narendra Modi signed an MoU on cooperation in the field of health and medicine between India and Australia, including focuses on communicable diseases; anti-microbial resistance; regulation of pharmaceuticals, vaccines and medical devices; and digital health.

Image supplied by MTPConnect.

Related News

Australian Academy of Science 2027 honorific awards — nominations close 1 May

Recognising outstanding contributions to the advancement of science, nominations for the Academy...

QIMR Berghofer signs strategic partnership with Nakanoshima Qross

QIMR Berghofer and Japanese biomedical innovation hub Nakanoshima Qross have signed a strategic...

Dr Chris Baldwin is new HaemaLogiX CEO and Managing Director

Having commenced in January, Dr Chris Baldwin is clinical stage Australian biotechnology company...


  • All content Copyright © 2026 Westwick-Farrow Pty Ltd